Investigational Drug Information for TA-8995
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for TA-8995?
TA-8995 is an investigational drug.
There have been 9 clinical trials for TA-8995.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Dyslipidemias, Alzheimer Disease, and [disabled in preview]. The leading clinical trial sponsors are Xention Ltd, Mitsubishi Tanabe Pharma Corporation, and NewAmsterdam Pharma.
There are three US patents protecting this investigational drug and seventy-eight international patents.
Summary for TA-8995
| US Patents | 3 |
| International Patents | 78 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 19 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2013-08-01) |
| Vendors | 8 |
Recent Clinical Trials for TA-8995
| Title | Sponsor | Phase |
|---|---|---|
| Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | NewAmsterdam Pharma | Phase 2 |
| Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 | Xention Ltd | Phase 1 |
| ADME Study in Healthy Male Subjects With TA-8995 | Xention Ltd | Phase 1 |
Clinical Trial Summary for TA-8995
Top disease conditions for TA-8995
Top clinical trial sponsors for TA-8995
US Patents for TA-8995
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TA-8995 | See Plans and Pricing | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | DEZIMA PHARMA B.V. (Naarden, NL) | See Plans and Pricing |
| TA-8995 | See Plans and Pricing | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | DEZIMA PHARMA B.V. (NL) | See Plans and Pricing |
| TA-8995 | See Plans and Pricing | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | DEZIMA PHARMA BV (NL) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TA-8995
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TA-8995 | Argentina | AR101509 | 2034-08-12 | See Plans and Pricing |
| TA-8995 | Australia | AU2015302407 | 2034-08-12 | See Plans and Pricing |
| TA-8995 | Brazil | BR112017002873 | 2034-08-12 | See Plans and Pricing |
| TA-8995 | Canada | CA2958040 | 2034-08-12 | See Plans and Pricing |
| TA-8995 | Chile | CL2017000367 | 2034-08-12 | See Plans and Pricing |
| TA-8995 | China | CN107108558 | 2034-08-12 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
